Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived A (Seite 4) | Diskussion im Forum
eröffnet am 15.01.20 11:44:07 von
neuester Beitrag 27.07.23 10:37:34 von
neuester Beitrag 27.07.23 10:37:34 von
Beiträge: 66
ID: 1.318.619
ID: 1.318.619
Aufrufe heute: 0
Gesamt: 3.575
Gesamt: 3.575
Aktive User: 0
ISIN: US00653A1079 · WKN: A14SUX · Symbol: 473A
1,0500
EUR
+0,96 %
+0,0100 EUR
Letzter Kurs 16:00:12 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 11,894 | +44,05 | |
| 2,5150 | +37,73 | |
| 2,9250 | +35,73 | |
| 1,0000 | +31,56 | |
| 3,9320 | +27,91 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2600 | -14,29 | |
| 7,8500 | -15,14 | |
| 1,5600 | -15,22 | |
| 5,0639 | -16,13 | |
| 0,5350 | -20,15 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 66.895.547 von Sven_Bonn am 09.02.21 08:42:05Halleluja....dürfte ein wahres Feuerwerk geben in 2021.
Guten Morgen zusammen,
eine schöne, aktuelle Unternehmenspräsentation:
https://www.adaptimmune.com/investors-and-media/company-info…
LG
Sven
eine schöne, aktuelle Unternehmenspräsentation:
https://www.adaptimmune.com/investors-and-media/company-info…
LG
Sven
Antwort auf Beitrag Nr.: 66.883.004 von bcgk am 08.02.21 16:01:04wunderbar !!!!!!
Jetzt hoffen wir auf gute Ergebnisse und dann das BO !!!!
Jetzt hoffen wir auf gute Ergebnisse und dann das BO !!!!
Trading Spotlight
Antwort auf Beitrag Nr.: 66.789.001 von Sven_Bonn am 03.02.21 09:00:37Charttechnik verspricht brisante Zeiten. Dier 50er hat die 200er geschnitten und der Kurs klebt nicht nur am Widerstand zwischen $6 und $6.50 sondern auch exakt an den beiden Durchschnitten. Etwas Druck und wir bekommen ein extrem bullisches Signal.
Antwort auf Beitrag Nr.: 66.787.570 von bcgk am 03.02.21 07:55:00Ja, das war gestern wunderbar.. Hoffen wir, dass jetzt noch ein paar tolle News folgen und sich dann die großen Pharmaunternehmen um uns reissen :-)
Antwort auf Beitrag Nr.: 66.489.185 von Sven_Bonn am 18.01.21 15:08:52Die $6 würde zurückerobert. Das Ziel bleibt mindestens der Bereich $10-11, wo zuletzt in größerem Umfang finanziert wurde.
Hallo zusammen,
dann scheint es ja im April mit News weiterzugehen....
https://twitter.com/Adaptimmune/status/1351169097535528960
LG
Sven
dann scheint es ja im April mit News weiterzugehen....
https://twitter.com/Adaptimmune/status/1351169097535528960
LG
Sven
Hallo zusammen,
gerade gefunden.. Aus meiner Sicht sieht es alles sehr vielversprechend aus.
LG
Sven
https://immuno-oncologynews.com/2021/01/15/t-cell-therapy-ad…
T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial
January 15, 2021 Marisa Wexler MSby Marisa Wexler MS
In News.
T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial
Click here to subscribe to the Immuno-Oncology News Newsletter!
5
(1)
ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that develops around the joints and tendons, new clinical trial data show.
The findings were presented at the Connective Tissue Oncology Society (CTOS) annual meeting by trial investigator Brian Van Tine, MD, PhD, of the Washington University School of Medicine. The oral presentation was titled, “Durable Responses in Patients with Synovial Sarcoma in the Phase I Trial of ADPA2M4 (MAGE-A4).“
“The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment. This leads to the highest quality of life I have been able to provide patients with synovial sarcoma after treatment,” Van Tine said in a press release.
T-cells are a type of immune cell that have the capacity to kill cancer cells. ADP-A2M4 is an autologous T-cell therapy, a form of treatment in which a patient’s own T-cells are collected, engineered to make them better at killing cancer, and then returned to the patient. Specifically, ADP-A2M4 involves T-cells with an engineered T-cell receptor (TCR) that targets the cancer-associated protein MAGE-A4.
These new findings come from an ongoing Phase 1 clinical trial (NCT03132922), which is evaluating the investigational therapy in multiple types of solid tumors. The trial, which is sponsored by ADP-A2M4’s developer Adaptimmune Therapeutics, is still enrolling at sites across the U.S. and in Canada. More information can be found here.
As of a September data cutoff date, 16 people with synovial sarcoma had been treated with ADP-A2M4. Their median age was 49, and all had received prior chemotherapy (median of 2.5 regimens). Prior to receiving ADP-A2M4, patients underwent lymphodepletion, which aims to kill immune cells already in the body.
The study’s main goal is to evaluate the safety profile of the investigational therapy. Thus far, results have been positive. The most common severe side effects were low levels of blood cells, which is consistent with the lymphodepletion regimen. Most (81%) participants experienced an inflammatory condition called cytokine release syndrome, but in most instances these cases were mild or moderate in severity.
One patient died of severe anemia (low red blood cell levels). After this death, the trial’s eligibility criteria and the treatment regimen used for lymphodepletion were modified.
Overall, seven (44%) of the patients responded to therapy, meaning their tumors got smaller after treatment. These responses were generally durable, lasting a median of 28 weeks (about six months). Two had ongoing responses that have lasted more than 72 weeks (nearly a year and a half).
An additional eight patients (50%) experienced stable disease with treatment, meaning no improvement or progression, amounting to a disease control rate of 94%.
Of the 16 participants, 11 are still alive, so that the median overall survival rate cannot yet be calculated.
Biological analyses indicated that patients whose tumors have higher MAGE-A4 expression are more likely to have more tumor reduction following treatment. Increased activity of an inflammatory signaling pathway called the interferon gamma pathway has also been associated with a better treatment response.
Adaptimmune is now running a pivotal Phase 2 trial (NCT04044768), called SPEARHEAD-1, to further evaluate ADP-A2M4 in people with synovial sarcoma. Results may support an application to regulatory authorities requesting the treatment’s approval for this indication. The trial is recruiting at various locations in North America and Europe; more information is available here.
“Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022,” said Adrian Rawcliffe, CEO of Adaptimmune.
gerade gefunden.. Aus meiner Sicht sieht es alles sehr vielversprechend aus.
LG
Sven
https://immuno-oncologynews.com/2021/01/15/t-cell-therapy-ad…
T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial
January 15, 2021 Marisa Wexler MSby Marisa Wexler MS
In News.
T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial
Click here to subscribe to the Immuno-Oncology News Newsletter!
5
(1)
ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that develops around the joints and tendons, new clinical trial data show.
The findings were presented at the Connective Tissue Oncology Society (CTOS) annual meeting by trial investigator Brian Van Tine, MD, PhD, of the Washington University School of Medicine. The oral presentation was titled, “Durable Responses in Patients with Synovial Sarcoma in the Phase I Trial of ADPA2M4 (MAGE-A4).“
“The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment. This leads to the highest quality of life I have been able to provide patients with synovial sarcoma after treatment,” Van Tine said in a press release.
T-cells are a type of immune cell that have the capacity to kill cancer cells. ADP-A2M4 is an autologous T-cell therapy, a form of treatment in which a patient’s own T-cells are collected, engineered to make them better at killing cancer, and then returned to the patient. Specifically, ADP-A2M4 involves T-cells with an engineered T-cell receptor (TCR) that targets the cancer-associated protein MAGE-A4.
These new findings come from an ongoing Phase 1 clinical trial (NCT03132922), which is evaluating the investigational therapy in multiple types of solid tumors. The trial, which is sponsored by ADP-A2M4’s developer Adaptimmune Therapeutics, is still enrolling at sites across the U.S. and in Canada. More information can be found here.
As of a September data cutoff date, 16 people with synovial sarcoma had been treated with ADP-A2M4. Their median age was 49, and all had received prior chemotherapy (median of 2.5 regimens). Prior to receiving ADP-A2M4, patients underwent lymphodepletion, which aims to kill immune cells already in the body.
The study’s main goal is to evaluate the safety profile of the investigational therapy. Thus far, results have been positive. The most common severe side effects were low levels of blood cells, which is consistent with the lymphodepletion regimen. Most (81%) participants experienced an inflammatory condition called cytokine release syndrome, but in most instances these cases were mild or moderate in severity.
One patient died of severe anemia (low red blood cell levels). After this death, the trial’s eligibility criteria and the treatment regimen used for lymphodepletion were modified.
Overall, seven (44%) of the patients responded to therapy, meaning their tumors got smaller after treatment. These responses were generally durable, lasting a median of 28 weeks (about six months). Two had ongoing responses that have lasted more than 72 weeks (nearly a year and a half).
An additional eight patients (50%) experienced stable disease with treatment, meaning no improvement or progression, amounting to a disease control rate of 94%.
Of the 16 participants, 11 are still alive, so that the median overall survival rate cannot yet be calculated.
Biological analyses indicated that patients whose tumors have higher MAGE-A4 expression are more likely to have more tumor reduction following treatment. Increased activity of an inflammatory signaling pathway called the interferon gamma pathway has also been associated with a better treatment response.
Adaptimmune is now running a pivotal Phase 2 trial (NCT04044768), called SPEARHEAD-1, to further evaluate ADP-A2M4 in people with synovial sarcoma. Results may support an application to regulatory authorities requesting the treatment’s approval for this indication. The trial is recruiting at various locations in North America and Europe; more information is available here.
“Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022,” said Adrian Rawcliffe, CEO of Adaptimmune.
Durchsuchen
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived A
